Fintel reports that on January 31, 2025, Canaccord Genuity downgraded their outlook for Intra-Cellular Therapies ...

The KSE-100 witnessed strong buying for the major part of the day, hitting an intra-day high of 115,106.99, a gain of around ...

In Sinaloa in northwestern Mexico, some residents say drug-fueled violence has gotten so bad that they would welcome U.S.

The top Republican on the Senate's health committee, Sen. Bill Cassidy, R-La., faced criticism from fellow Republicans after ...

The largest city in Tennessee is set to welcome flights to Austin, Nashville, New Orleans, and Fort Lauderdale over the next ...

AURORA, Colo. -- Adverse maternal outcomes, particularly sepsis, increased in pregnancies with previable premature rupture of ...

Visa Inc (V) reports a robust start to the fiscal year with significant gains in revenue and international transactions, ...

Marvel Kart by Excel Public School students aims to improve intra-city travel for disabled individuals, reaching CBSE Skill ...

Markets in Indian are poised to open with an upside, amid firm global cues, as investors track the start of the Budget ...

Research has shown the potential for artificial intelligence (AI) to assist in the diagnosis of conditions, like endometriosis, but what happens if the modeling is incorrect?

Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...

Benchmark equity indices BSE Sensex and NSE Nifty50 were higher for the fourth straight day in the run-up to the presentation ...